PT2635257T - Partículas semelhantes a vírus de glicoproteína de raiva (vlps) - Google Patents

Partículas semelhantes a vírus de glicoproteína de raiva (vlps)

Info

Publication number
PT2635257T
PT2635257T PT118389428T PT11838942T PT2635257T PT 2635257 T PT2635257 T PT 2635257T PT 118389428 T PT118389428 T PT 118389428T PT 11838942 T PT11838942 T PT 11838942T PT 2635257 T PT2635257 T PT 2635257T
Authority
PT
Portugal
Prior art keywords
vlps
river
particles similar
glycoprotein virus
glycoprotein
Prior art date
Application number
PT118389428T
Other languages
English (en)
Portuguese (pt)
Inventor
Smith Gale
Liu Ye
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of PT2635257T publication Critical patent/PT2635257T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/205Rhabdoviridae, e.g. rabies virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20111Lyssavirus, e.g. rabies virus
    • C12N2760/20134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT118389428T 2010-11-05 2011-11-07 Partículas semelhantes a vírus de glicoproteína de raiva (vlps) PT2635257T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41076710P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
PT2635257T true PT2635257T (pt) 2017-08-16

Family

ID=46025156

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118389428T PT2635257T (pt) 2010-11-05 2011-11-07 Partículas semelhantes a vírus de glicoproteína de raiva (vlps)

Country Status (22)

Country Link
US (3) US9724405B2 (OSRAM)
EP (2) EP2635257B1 (OSRAM)
JP (2) JP6158088B2 (OSRAM)
KR (1) KR101847908B1 (OSRAM)
CN (2) CN103282023B (OSRAM)
AU (1) AU2011323090B2 (OSRAM)
BR (1) BR112013011194B1 (OSRAM)
CA (1) CA2817005C (OSRAM)
CY (1) CY1119284T1 (OSRAM)
DK (1) DK2635257T3 (OSRAM)
ES (1) ES2636965T3 (OSRAM)
HR (1) HRP20171213T1 (OSRAM)
HU (1) HUE034247T2 (OSRAM)
LT (1) LT2635257T (OSRAM)
MX (1) MX354750B (OSRAM)
PL (1) PL2635257T3 (OSRAM)
PT (1) PT2635257T (OSRAM)
RS (1) RS56157B1 (OSRAM)
SG (1) SG190140A1 (OSRAM)
SI (1) SI2635257T1 (OSRAM)
SM (1) SMT201700392T1 (OSRAM)
WO (1) WO2012061815A2 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
ES2554703T3 (es) 2007-11-27 2015-12-22 Medicago Inc. Partículas recombinantes semejantes al virus de la influenza (VLP) producidas en plantas transgénicas que expresan hemaglutinina
DK2370099T3 (en) 2008-12-09 2016-08-01 Novavax Inc Rsv f modified proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
MX2012003372A (es) 2009-09-22 2012-05-29 Medicago Inc Metodo para preparar proteina derivada de vegetales.
PT2635257T (pt) * 2010-11-05 2017-08-16 Novavax Inc Partículas semelhantes a vírus de glicoproteína de raiva (vlps)
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
BR112013032033A2 (pt) * 2011-06-13 2017-05-30 Medicago Inc produção de partícula simular ao vírus da raiva em plantas
KR101479668B1 (ko) 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN103777021B (zh) * 2012-10-18 2016-03-02 辽宁成大生物股份有限公司 狂犬疫苗糖蛋白含量的检测方法
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
ES2975182T3 (es) 2017-03-06 2024-07-03 Guangzhou Realbenefitspot Pharmaceutical Co Ltd Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
WO2019086645A1 (en) * 2017-11-06 2019-05-09 Intervet International B.V. Rabies virus vaccine
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11278612B2 (en) 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
KR102077772B1 (ko) 2018-11-29 2020-02-17 주식회사 바이오앱 광견병 예방용 백신 조성물 및 이의 제조 방법
KR102211077B1 (ko) * 2019-01-16 2021-02-02 충남대학교 산학협력단 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN110007080B (zh) * 2019-04-12 2022-09-23 长春西诺生物科技有限公司 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法
CN109959789B (zh) * 2019-04-12 2022-08-16 长春西诺生物科技有限公司 一种狂犬病毒抗体检测试纸及其制备方法与检测方法
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2023064931A1 (en) * 2021-10-15 2023-04-20 La Jolla Institute For Immunology Engineered rabies virus glycoprotein, compositions, and methods of use thereof
CN114272367B (zh) * 2021-12-03 2023-07-07 华东理工大学 一种口服狂犬病病毒样颗粒疫苗及其制备方法
KR102566969B1 (ko) 2021-12-14 2023-08-16 안희철 근거리 통신 과정에서 충전 가능한 모바일 단말
CN117867029B (zh) * 2023-12-29 2024-12-20 复百澳(苏州)生物医药科技有限公司 一种狂犬亚型假病毒的制备方法及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5667782A (en) 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6589533B1 (en) * 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
US6673601B1 (en) * 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2003047493A2 (en) * 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
KR20080094910A (ko) * 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
WO2007144886A2 (en) * 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
EP2035565A4 (en) * 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
US8980281B2 (en) * 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
CN101801412A (zh) * 2007-07-19 2010-08-11 诺瓦瓦克斯股份有限公司 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原
KR100961280B1 (ko) * 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
WO2009153801A1 (en) * 2008-06-17 2009-12-23 Manpreet Kaur Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
DK2370099T3 (en) 2008-12-09 2016-08-01 Novavax Inc Rsv f modified proteins and methods of their use
PT2635257T (pt) 2010-11-05 2017-08-16 Novavax Inc Partículas semelhantes a vírus de glicoproteína de raiva (vlps)

Also Published As

Publication number Publication date
MX354750B (es) 2018-03-20
US20190224307A1 (en) 2019-07-25
CN109157658A (zh) 2019-01-08
CA2817005A1 (en) 2012-05-10
BR112013011194B1 (pt) 2020-12-22
EP3246019A1 (en) 2017-11-22
JP6158088B2 (ja) 2017-07-05
DK2635257T3 (en) 2017-09-04
CY1119284T1 (el) 2018-02-14
CN103282023A (zh) 2013-09-04
US10086065B2 (en) 2018-10-02
LT2635257T (lt) 2017-09-25
WO2012061815A2 (en) 2012-05-10
EP3246019B1 (en) 2021-03-03
AU2011323090B2 (en) 2015-02-12
JP2017035093A (ja) 2017-02-16
JP2014500013A (ja) 2014-01-09
EP2635257B1 (en) 2017-07-05
JP6195965B2 (ja) 2017-09-13
US20140178419A1 (en) 2014-06-26
EP2635257A4 (en) 2014-04-02
PL2635257T3 (pl) 2017-10-31
SG190140A1 (en) 2013-06-28
BR112013011194A2 (pt) 2017-06-27
AU2011323090A1 (en) 2013-04-04
HRP20171213T1 (hr) 2017-10-20
CA2817005C (en) 2018-09-11
KR20130111581A (ko) 2013-10-10
SMT201700392T1 (it) 2017-09-07
ES2636965T3 (es) 2017-10-10
EP2635257A2 (en) 2013-09-11
RS56157B1 (sr) 2017-11-30
WO2012061815A3 (en) 2013-03-14
US9724405B2 (en) 2017-08-08
US20180021428A1 (en) 2018-01-25
CN103282023B (zh) 2018-09-21
MX2013005090A (es) 2013-10-25
SI2635257T1 (en) 2018-01-31
HUE034247T2 (en) 2018-02-28
RU2013125695A (ru) 2014-12-10
KR101847908B1 (ko) 2018-04-11

Similar Documents

Publication Publication Date Title
PT2635257T (pt) Partículas semelhantes a vírus de glicoproteína de raiva (vlps)
SMT201600386B (it) Particelle di rilascio simili a virioni per molecole di rna auto-replicanti
EP2307549A4 (en) INFLUENZA VIRUS TYPE (VLP) PARTICLES COMPRISING HEMAGGLUTININ
DK3447131T3 (da) Influenza a-virusmutanter
DK3424532T3 (da) Influenzavirus-antistofsammensætninger
SG11201402780UA (en) Influenza a virus specific antibodies
PT3556396T (pt) Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
EP2786090A4 (en) SOLDERABLE MAGAZINE BAG
BR112013024415A2 (pt) monômeros funcionalizados
BR112014000787A2 (pt) método para produzir vírus vaccinia
BR112014005214A2 (pt) modificador de fluxo de exaustão de pré-injeção
IL225853A0 (en) Inhibitors of hepatitis c virus
DK2993183T3 (da) Anti-hpv e7-antistoffer
PT2655613T (pt) Produção de partículas semelhantes a vírus em plantas
IL227789A0 (en) Hepatitis c virus inhibitors
IL232662A0 (en) Processes used in vlps with viral envelopes that are resistant to hydrolysis
IL229270A0 (en) Hepatitis c virus inhibitors
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
EP2785842A4 (en) CHIMERIC HPV PARTICLES
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
IT1403272B1 (it) Strutture oligomeriche complesse
HUE043576T2 (hu) Antitestek notum pektinacetilészterázhoz
FI20090030A0 (fi) Onkolyyttiset virukset
EP2740496A4 (en) ANTI-ADHESIONING MEMBRANE
GB201015305D0 (en) Methods, compounds and compositions relating to activating a latent virus